Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation.
Publication/Presentation Date
2-1-2021
Abstract
INTRODUCTION: Oral anticoagulation (OAC) based on estimated stroke risk is recommended following catheter ablation (CA) of atrial fibrillation (AF), regardless of the extent of arrhythmia control. However, discontinuing OAC in selected patients may be safe. We sought to evaluate a strategy of OAC discontinuation following AF ablation guided by continuous rhythm monitoring.
METHODS AND RESULTS: We prospectively studied AF ablations performed at our institution from June 2015 to December 2019. Patients that had pre-existing cardiac implantable electronic devices (CIEDs) or underwent insertable cardiac monitor (ICM) implantation immediately following AF ablation were included. OAC was continued for 6 weeks following CA in all patients, following which OAC management was guided by CHA
CONCLUSION: OAC can be discontinued in a significant percentage of patients following CA of AF. When guided by continuous rhythm monitoring, this practice does not unacceptably increase the risk of thromboembolic events.
Volume
32
Issue
2
First Page
345
Last Page
353
ISSN
1540-8167
Published In/Presented At
Pothineni, N. V. K., Amankwah, N., Santangeli, P., Schaller, R. D., Supple, G. E., Deo, R., Nazarian, S., Garcia, F. C., Dixit, S., Callans, D. J., Marchlinski, F. E., & Frankel, D. S. (2021). Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation. Journal of cardiovascular electrophysiology, 32(2), 345–353. https://doi.org/10.1111/jce.14864
Disciplines
Medicine and Health Sciences
PubMedID
33382500
Department(s)
Department of Medicine
Document Type
Article